FDA expands access to experimental melanoma drug

	Tweet

Maxim Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration had allowed it to expand advanced testing of a drug for treating skin cancer.

The FDA ruling will enable more patients to use the drug Ceplene—in combination with the drug interleukin-2—for treatment of advanced malignant melanoma, the Swedish-American drug firm said.

The decision allows it to “provide expanded access of Ceplene to patients in the United States while investigation of the drug continues in the company’s confirming phase III clinical trial,” Maxim said in a statement.

Phase III trials are the last stage of testing before a company submits all documents to the FDA and requests full approval of the drug for commercial release. The development is a further step toward the drug coming onto the market.

Maxim’s shares were up 4.5 percent at 69.50 crowns at 1015 GMT, after earlier rising as high as 71 crowns, in a Swedish market whose blue-chip OMX index was off 1.4 percent.

Analysts said there was more upside potential in the stock.

“We see the information concerning the FDA’s decision about the product Ceplene as being very positive,” said Swedish growth stock analysts Redeye. “We see today’s initial share price rise as being on the small side.”

RELATED STORIES:
Changing Lifestyle May Help to Combat Cancer   Turning a painkiller into a cancer killer   Chief Justice Rehnquist Has Thyroid Cancer   New breast cancer detection method promising   Alzheimer’s Disease May Protect Against Cancer and Vice Versa   Lawson researchers take control of cancer   Nicotine metabolism among African American and white smokers   Another study finds no cell phone-brain cancer link   Ovarian cancer: Not the ‘silent killer’ it was   Cancer Drug Experiments Getting Safer for Humans   Fear cancer will increase   40 years later, Nagasaki bomb still causes disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]